Skip to main content
. 2021 May 18;27(6):1071–1078. doi: 10.1038/s41591-021-01370-1

Table 1.

Summary of demographics and baseline characteristics (NCT04450004)

CoVLP 3.75 µg CoVLP 7.5 µg CoVLP 15 µg All
Unadjuvanted Adjuvanted with CpG 1018 Adjuvanted with AS03 Unadjuvanted Adjuvanted with CpG 1018 Adjuvanted with AS03 Unadjuvanted Adjuvanted with CpG 1018 Adjuvanted with AS03
Participants 20 20 20 20 20 20 20 20 20 180
Sex, n (%)
 Male 9 (45.0) 10 (50.0) 5 (25.0) 10 (50.0) 8 (40.0) 8 (40.0) 7 (35.0) 10 (50.0) 11 (55.0) 78 (43.3)
 Female 11 (55.0) 10 (50.0) 15 (75.0) 10 (50.0) 12 (60.0) 12 (60.0) 13 (65.0) 10 (50.0) 9 (45.0) 102 (56.7)
Race, n (%)
 White 18 (90.0) 20 (100.0) 20 (100.0) 20 (100.0) 18 (90.0) 19 (95.0) 20 (100.0) 18 (90.0) 19 (95.0) 172 (95.6)

 Black or African

American

1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 0 (0.0) 1 (5.0) 1 (5.0) 4 (2.2)
 Asian 1 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 1 (5.0) 0 (0.0) 1 (5.0) 0 (0.0) 4 (2.2)
Ethnicity, n (%)
 Hispanic/Latinx 0 (0.0) 2 (10.0) 0 (0.0) 1 (5.0) 3 (15.0) 1 (5.0) 0 (0.0) 1 (5.0) 0 (0.0) 9 (5.0)
Age at vaccination
 Mean ± s.d. 34.9 ± 8.3 35.3 ± 11.0 34.7 ± 9.1 35.6 ± 8.0 32.4 ± 9.5 37.2 ± 7.8 34.1 ± 9.6 32.0 ± 9.0 32.7 ± 9.1 34.3 ± 9.0
 Median (range) 35 (18–49) 36 (18–53) 36 (19–49) 36 (20–50) 31 (19–52) 37 (21–55) 31.5 (22–54) 30 (19–51) 32.5 (18–52) 34 (18–55)